Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/23068
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | BILLIET, Charlotte | - |
dc.contributor.author | Peeters, Stephanie | - |
dc.contributor.author | Decaluwe, Herbert | - |
dc.contributor.author | Vansteenkiste, Johan | - |
dc.contributor.author | MEBIS, Jeroen | - |
dc.contributor.author | De Ruysscher, Dirk | - |
dc.date.accessioned | 2017-02-06T10:52:30Z | - |
dc.date.available | 2017-02-06T10:52:30Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | CANCER TREATMENT REVIEWS, 51, p. 10-18 | - |
dc.identifier.issn | 0305-7372 | - |
dc.identifier.uri | http://hdl.handle.net/1942/23068 | - |
dc.description.abstract | Introduction: The role of postoperative radiation therapy (PORT) in patients with completely resected non-small cell lung cancer (NSCLC) with pathologically involved mediastinal lymph nodes (N2) remains unclear. Despite a reduction of local recurrence (LR), its effect on overall survival (OS) remains unproven. Therefore we conducted a review of the current literature. Methods: To investigate the benefit and safety of modern PORT, we identified published phase III trials for PORT. We investigated modern PORT in low-risk (ypN0/1 and RO) and high-risk (ypN2 and/or R1/2) patients with stage III-N2 NSCLC treated with induction chemotherapy and resection. Results: Seventeen phase III trials using PORT were selected. Of all PORT N2 studies, 4 were eligible for evaluation of LR, all in high-risk patients only. In these high-risk patients receiving PORT, the mean LR rate at 5 years was 20.9% (95% CI 16-24). Two trials were suitable to assess LR rates after chemotherapy and surgery without PORT. In these low-risk patients, the mean 5-year LR was 33.1% (95% CI 27-39). No significant difference in non-cancer deaths between PORT vs. non-PORT patients was observed in N2 NSCLC. Conclusion: PORT is worth the controversy because data illustrate that PORT may increase the OS. However, prospective randomized trials are needed to verify this. (C) 2016 Elsevier Ltd. All rights reserved. | - |
dc.description.sponsorship | This study is part of the Limburg Clinical Research Program (LCRP) UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk, province of Limburg, Flemish government, Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital; This work was supported by the Limburg Cancer Foundation and Kom op tegen Kanker. | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.rights | (C) 2016 Elsevier Ltd. All rights reserved. | - |
dc.subject.other | Post-operative radiotherapy; Non-small-cell lung cancer; Review | - |
dc.subject.other | post-operative radiotherapy; non-small-cell lung cancer; review | - |
dc.title | Postoperative radiotherapy for lung cancer: Is it worth the controversy? | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 18 | - |
dc.identifier.spage | 10 | - |
dc.identifier.volume | 51 | - |
local.format.pages | 9 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Billiet, Charlotte; Peeters, Stephanie; De Ruysscher, Dirk] Katholieke Univ Leuven, Univ Leuven, Dept Radiat Oncol, B-3000 Louvain, Belgium. [Billiet, Charlotte; Mebis, Jeroen] Hasselt Univ, Fac Med & Life Sci, Martelarenlaan 42, B-3500 Hasselt, Belgium. [Decaluwe, Herbert] Katholieke Univ Leuven, Univ Leuven, Dept Thorac Surg, B-3000 Louvain, Belgium. [Decaluwe, Herbert; Vansteenkiste, Johan] Leuven Lung Canc Grp, B-3000 Louvain, Belgium. [Vansteenkiste, Johan] Katholieke Univ Leuven, Univ Leuven, Dept Pneumol, Resp Oncol Unit, B-3000 Louvain, Belgium. [Mebis, Jeroen] Jessa Hosp, Dept Med Oncol, B-3500 Hasselt, Belgium. [De Ruysscher, Dirk] Maastricht Univ, Med Ctr, GROW, Dept Radiat Oncol MAASTRO, Maastricht, Netherlands. | - |
local.publisher.place | OXFORD | - |
local.type.refereed | Refereed | - |
local.type.specified | Review | - |
dc.identifier.doi | 10.1016/j.ctrv.2016.10.001 | - |
dc.identifier.isi | 000389293900002 | - |
item.fullcitation | BILLIET, Charlotte; Peeters, Stephanie; Decaluwe, Herbert; Vansteenkiste, Johan; MEBIS, Jeroen & De Ruysscher, Dirk (2016) Postoperative radiotherapy for lung cancer: Is it worth the controversy?. In: CANCER TREATMENT REVIEWS, 51, p. 10-18. | - |
item.validation | ecoom 2018 | - |
item.contributor | BILLIET, Charlotte | - |
item.contributor | Peeters, Stephanie | - |
item.contributor | Decaluwe, Herbert | - |
item.contributor | Vansteenkiste, Johan | - |
item.contributor | MEBIS, Jeroen | - |
item.contributor | De Ruysscher, Dirk | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
crisitem.journal.issn | 0305-7372 | - |
crisitem.journal.eissn | 1532-1967 | - |
Appears in Collections: | PhD theses Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
billiet 1.pdf Restricted Access | Published version | 654.21 kB | Adobe PDF | View/Open Request a copy |
postoperative author.pdf | Peer-reviewed author version | 872.22 kB | Adobe PDF | View/Open |
Tables.pdf | Supplementary material | 717.71 kB | Adobe PDF | View/Open |
SI.pdf | Supplementary material | 292.26 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
9
checked on Sep 5, 2020
WEB OF SCIENCETM
Citations
19
checked on May 8, 2024
Page view(s)
66
checked on Sep 7, 2022
Download(s)
408
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.